Gun­ning for 2023 ap­proval, GSK de­tails PhI­II da­ta for Jem­per­li in front­line en­dome­tri­al can­cer

GSK has a new slate of da­ta to of­fer on its PD-1 in­hibitor, Jem­per­li — da­ta that the phar­ma gi­ant hopes will ce­ment one of the four drug ap­provals it’s ex­pect­ing this year.

While Jem­per­li (dostar­limab) is al­ready ap­proved for a sub­set of pa­tients with sec­ond-line en­dome­tri­al can­cer, GSK set out in the Phase III RU­BY tri­al to test it as an ear­li­er line of treat­ment while al­so en­rolling a broad­er group of pa­tients. In an in­ter­im analy­sis, Jem­per­li was shown to ex­tend pro­gres­sion-free sur­vival for both the sub­set and the over­all tri­al pop­u­la­tion when added to chemother­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER